David Green tells MassDevice.com about the decision to split Harvard Bioscience and Harvard Apparatus Regenerative Technology, his choice to move over to the new entity and why regenerative technologies are poised to transform medicine.
Medtech veteran Dave Johnson has been with Alliqua Biomedical for less than 2 years, during which time he's overseen a major hiring spree, 3 business development deals and the company's 1st acquisition. In an interview with MassDevice.com, Johnson talks about his step-by-step perspective and where he hopes Alliqua will be in 5 years.
Say hello to MassDevice +3, a bite-sized view of the top three medtech stories of the day. This feature of MassDevice.com's coverage highlights our 3 biggest and most influential stories from the day's news to make sure you're up to date on the headlines that continue to shape the medical device industry.
The FDA asks medical device manufacturers to submit documentation about controls they have in place to mitigate the threat of hackers accessing their devices, including ongoing software patches and updates to operating systems.
The FDA is asking medical device manufacturers to submit documentation about cybersecurity controls they have in place to mitigate the threat of hackers accessing devices, including ongoing software patches and updates to operating systems.
Orange County, Calif.'s most-connected man, OCTANe's Matthew Jenusaitis talks to MassDevice.com about OCTANe's 2014 Medical Device Investor Forum.
OCTANe, the industry council responsible for promoting the innovation climate in Orange County, Calif., existed before Matthew Jenusaitis arrived, but he has put his mark on the organization's impact on one of the world's largest med tech clusters.
EndoStim hopes to raise $36 million in an initial public offering to support development of a pacemaker-like device to treat severe gastroesophageal reflux disease.
EndoStim said it hopes to raise nearly $36 million in an initial public offering, with plans to plow $10 million into clinical studies of its system to treat severe gastroesophageal reflux disease and another $14 million to commercialize the system.